Anti-angiogenesis therapy for the treatment of ovarian cancer

Details for Australian Patent Application No. 2011221229 (hide)

Owner F. Hoffmann-La Roche AG GENENTECH, INC.

Inventors Dupont, Jakob; Irl, Cornelia

Agent Griffith Hack

Pub. Number AU-A-2011221229

PCT Pub. Number WO2011/106300

Priority 61/439,819 04.02.11 US; 61/351,231 03.06.10 US; 61/307,095 23.02.10 US; 61/360,059 30.06.10 US

Filing date 22 February 2011

Wipo publication date 1 September 2011

International Classifications

C07K 16/22 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/282

A61K 31/337 - having four-membered rings, e.g. taxol

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

16 August 2012 PCT application entered the National Phase

  PCT publication WO2011/106300 Priority application(s): WO2011/106300

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011221235-Microcavity oleds for lighting

2011221227-BRAF mutations conferring resistance to BRAF inhibitors